Hotline 24/7: 0909384389

Share links:

“Positive outlook” for transcatheter edge-to-edge treatment of mitral regurgitation

Ngày 30/11/2020 01:24 | Lượt xem: 943

Emerging data supports transcatheter techniques to treat primary mitral regurgitation, according to KK Yeo (National Heart Center, Singapore) who presented at PCR Valves 2020 (22–24 November, virtual) discussing the latest developments in edge-to-edge repair for primary mitral regurgitation.

Yeo discussed data from the EXPAND Registry, documenting real-world outcomes from the third generation MitraClip (Abbott) NTR and XTR systems, as well as looking ahead to further studies and technological developments in the field.

“What is important and impressive is that procedure time had improved from 135 minutes to 82 minutes in the EXPAND registry, and the length of stay has improved from three days to one day in terms of the median duration,” said Yeo, commenting on data initially presented at the American College of Cardiology/World Congress of Cardiology’s virtual scientific sessions (ACC.20/WCC Virtual) in March, with further data also presented during a late-breaking session at PCR Valves.

Further evidence on the efficacy of the device are expected to be gathered through the REPAIR MR trial, Yeo commented, which will compare the clinical outcomes of the Mitraclip to surgical repair in patients with severe primary MR who are at moderate surgical risk.

Additionally, Yeo highlighted data from the CLASP trial, evaluating the safety and performance of the Pascal system (Edwards Lifesciences), which was presented in the summer, and found that the device was associated with a low complication rate and high survival rate in the treatment of mitral regurgitation.

These developments lead Yeo to conclude that new generation devices “offer more treatment options” and added that through the emergence of the Pascal device, competition has arrived in the mitral device market—representing a positive outlook for transcatheter treatment options.

Following Yeo, Stephan Baldus (University Heart Center Cologne, Cologne, Germany) appraised the evidence for edge-to-edge repair in secondary mitral regurgitation patients. “Within the last couple of years, we have witnessed a sound body of evidence showing that secondary mitral regurgitation is not only a bystander, but it’s a driver of disease in patients with systolic heart failure,” he said, in the opening slide of his presentation.

Baldus commented on the rapid adoption of transcatheter mitral techniques in functional mitral regurgitation patients, commenting that the edge-to-edge repair is the “driving procedure for these patients in functional mitral regurgitation”. He commented that in terms of safety, the procedure has been shown to be safe out to five years, “If we combine all of this we can bascially say that mortality throughout these registries is below 4% nowadays, the stroke rate is exceptionally, below 1% and single leaflet detachment is below 2%, so it is a really safe procedure for secondary mitral regurgitation.

With respect to efficacy edge-to-edge repair is non-inferior to mitral valve surgery in patients with functional mitral regurgitation, Baldus commented. “The TVT Registry, the EXPAND Registry, as well as randomised trials in these patients, show that procedural success has increased to over 90% with 75% or more indicative of a mitral regurgitation grade below 1 or 90% of these patients showing an MR grade of below 2 in functional regurgitation.

“We have to be good at reducing mitral regurgitation because we know that the grade of residual MR determines the fate of the patient. Patients who are leaving the hospital with an MR grade of 1 or below actually have the best prognosis. It is interesting to see that we need to be sure that this is sustained over the next 12 months.”

In a later session, looking at innovations in surgical and transcatheter mitral valve intervention, Paul Sorajja (Minneapolis Heart Institute, Minneapolis, USA) discussed the latest developments in transcatheter mitral valve technology.

“While we all know that transcatheter mitral valve replacement was pioneered with transapical devices, many new technologies have been moving towards the transseptal approach,” Sorajja commented. He noted that Sapien M3 (Edwards Lifesciences), Evoque (Edwards Lifesciences), Alta (4C Medical) are among the devices to have been implanted using this approach to date.

“One of the newest entrants is the Medtronic Intrepid system,” he said. “This is the same valve that was used in a transapical approach as part of the feasibility study and this is now a transseptal system that is 35 French, and the first patient was treated in February. There are plans for an early feasibility study at 15 patients among those who are not eligible for surgery.”

Sorajja also mentioned the HighLife Valve (HighLife Medical)—describing this as a hybrid approach of a transvenous and a transarterial system in which a ring is used to manage the mitral leaflets and also anchor the device. “This approach helps to minimise device profile and potentially enables patients who were previously excluded due to potential LVT obstruction,” he said

For repair technologies, he highlighted the Millipede system by Boston Scientific which he said is shortly to begin an early feasibility study. ”This highlights a strong desire for a toolkit approach for catheter interventions akin to open surgery,” he commented, adding that “percutaneous angioplasty could be an adjunct as it is permissive technology or be a standalone therapy”.

Finally he added that the ability to perform transcatheter repair as well as replacement in the same patient is also emerging. He detailed a first-in-human example of a patient who had initially had successful MitraClip implantation, but recurrent MR. His team performed percutaneous laceration of the tissue bridge followed by placement of the Tendyne (Abbott) TMVR device.

Source CardiovascularNews

Duc Tin Clinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support